Refine by
Disease Monitoring Articles & Analysis
60 news found
The scientists will collect blood from the patients and will measure the number and kind of tumor cells (cellular residual disease) and DNA (molecular residual disease) released from the tumor in the blood. ...
This non-invasive testing allows for cancer genomic profiling and disease monitoring. It reveals critical insights in many cases where genomic testing of tumor tissue may not be feasible due to insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure. ...
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual ...
ByTempus
Whether researchers are on the hunt for novel microbial species, investigating disease etiology, conducting environmental monitoring, or studying microbial communities in the context of human health, CD Genomics' service can provide robust support and accurate data. ...
” Lifespin is working to build new precision medicine tools based on quantitative metabolic profiles and proprietary algorithms to assist in the early detection of diseases and monitoring the efficacy of health treatments. To facilitate these services, the company has established one of the largest and most comprehensive databases of metabolic health ...
” Jack Syage, PhD and CEO of ImmunogenX, states, “We are excited by the continued success of latiglutenase as a leading therapeutic candidate for celiac disease patients as an adjunct to a gluten-free diet. Our mission to improve the lives of celiac disease patients is inspired by members of our team who are afflicted with this ...
Asymptomatic precursor stages such as monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) can be highly heterogeneous in terms of their risk of progression and the lack of tools to monitor this population represents a critical unmet medical need. Current standard of care involves invasive BM biopsies to understand ...
“The body of data from MANIFEST further suggests that pelabresib may provide both symptom relief and potentially disease modification, helping fulfill unmet needs for patients with ...
Immediate applications of Lifespin’s commercial services, which leverages access to Lifespin’s proprietary software and database, include quality control for synthetic/natural compounds, quantitative profiling of metabolites in liquid samples, monitoring of drug responses and organ-specific metabolic phenotyping, and precision nutrition to therapeutic drug ...
“Exosomes are a rapidly growing research area for biomarker discovery and the diagnosis and treatment of cancer and other diseases.” “There are different purposes for INOVIQ’s diagnostic products, from screening to detect disease earlier in asymptomatic people, through to diagnosis of disease and then ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
(NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progression, today announced that positive results of analytical and clinical studies of Bluejay’s Symphony IL-6 Test were presented at AACC 2022, the leading ...
(NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced completion of its previously planned clinical studies for the Symphony IL-6 Test (the “Test”). ...
The IND was approved by the US FDA Division of Medical Imaging and Radiation Medicine (DMIRM), which is responsible for drug products used in the image-based diagnosis and monitoring of diseases (Clinicaltrials.gov: NCT04420689). The study will proceed at three sites, including the University of California at San Diego (UCSD), Stanford Medical Center and ...
(NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test. ...
(NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin “Ed” E. ...
NDD Medical Technologies (NDD), a leading provider of diagnostic technology enabling healthcare professionals the early detection of COPD and other chronic lung diseases, has updated the entire EasyOne® product range, including the EasyOne Air, Easy on-PC, EasyOne Pro, and EasyOne Pro LAB, to be compliant with the ATS/ERS Standardization of Spirometry 2019. Spirometry is ...
“Variability and subjectivity persist in the radiological assessment of MRI biomarkers, which are core components of the MS diagnostic workup and monitoring of disease progression. Today, this can be addressed by more systematically integrating the use of automated methods in clinical practice, to drive better clinical care and outcomes for MS ...
ByQynapse
“End-stage renal disease, one of the costliest chronic diseases in the U.S., is devastating to patients. ...
The company will act as a primary lab partner, operating C2i’s whole-genome sequencing (WGS) and minimal-residual disease (MRD) cancer monitoring platform for European clinical research projects. ...